Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.32 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586069 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL431258 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL23346884 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL15717047 | 0.76 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL20622379 | 0.75 | ALDH1A1 (0.35) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL18761410 | 0.73 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL15717188 | 0.72 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL432343 | 0.70 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL30574315 | 0.70 | NOTUM (0.55) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL14275844 | 0.70 | NOTUM (0.55) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC6A2 968/4885SLC6A3 623/4885SLC6A4 701/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC6A2 1014/4885SLC6A3 662/4885SLC6A4 743/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | SLC6A2 968/4885SLC6A3 623/4885SLC6A4 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.